William Newton is a Senior Healthcare Reporter at 340B Report. He specializes in healthcare journalism with a focus on drug pricing policy, patient care, and public health, while also exploring themes in law, politics, and the intersection of arts and healthcare. His work has been featured in Clinical Trials Arena, The Spectator World, Yahoo Finance, Berkeleyside, BioRxiv, and SALINA GUNS AND HOSES.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
William Newton's coverage is heavily focused on the healthcare and pharmaceutical industry, particularly clinical trials, drug development, and disease-specific research. He frequently cites data and press releases to support his articles.
Given this focus, William may be most receptive to pitches that offer access to exclusive data or insights from experts in the pharmaceutical industry. Pitches related to breakthroughs in drug development, innovative approaches to clinical trials such as decentralized trials, and advancements in treating specific diseases like Alzheimer's or epilepsy are likely to align with his coverage interests.
If you have relevant data or expertise within the pharmaceutical industry or specific disease areas covered by William, your pitch could resonate well with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
A meal largely of hors d’oeuvres and leftovers.
By: William Newton
A Boston federal appeals court this week heard oral arguments in two high-stakes drugmaker legal challenges to 340B contract pharmacy [...] Please Login or Become a Paid Subscriber to View this Content
The federal government recently urged a federal judge to dismiss AbbVie's lawsuit challenging HRSA's longstanding definition of a 340B patient. [...] Please Login or Become a Paid Subscriber to View this Content
U.S. Sen. Bill Cassidy (R-La.) released sweeping 340B draft legislation Thursday morning that would allow drug manufacturers to offer 340B [...] Please Login or Become a Paid Subscriber to View this Content
Four major drugmakers recently renewed their push to dismiss a California health system's 340B overcharge whistleblower lawsuit—just months after a [...] Please Login or Become a Paid Subscriber to View this Content
A major North Carolina health system on Friday appeared to settle two lawsuits alleging health insurer Humana underpaid for 340B [...] Please Login or Become a Paid Subscriber to View this Content
A Washington, D.C. federal appeals court today upheld HHS' authority to require drugmakers to seek approval before implementing 340B rebate [...] Please Login or Become a Paid Subscriber to View this Content
A new Missouri law prohibiting pharmacy benefit managers (PBMs) and health insurers from “discriminating” against 340B grantee covered entities and [...] Please Login or Become a Paid Subscriber to View this Content
HRSA has contacted certain 340B providers about agreements with their contract pharmacies that could be released to French drugmaker Sanofi [...] Please Login or Become a Paid Subscriber to View this Content
The Trump administration is expected to move oversight of the 340B program from its longtime home at HRSA to CMS, [...] Please Login or Become a Paid Subscriber to View this Content
